Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference
02 1월 2024 - 10:00PM
Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company
committed to delivering a new class of differentiated one-time
curative genetic therapies, today announced that Keith
Gottesdiener, M.D., President and Chief Executive Officer of Prime
Medicine, will present a corporate overview at the 42nd Annual J.P.
Morgan Healthcare Conference on Monday, January 8, 2024 at 2:15
p.m. PT (5:15 p.m. ET) in San Francisco, CA.
A live audio webcast of the presentation will be available under
“Events & Presentations” in the News & Events section of
the Company’s website at www.primemedicine.com. A replay of the
webcast will be available on the Prime Medicine website for 30 days
following the presentation.
About Prime MedicinePrime Medicine is a leading
biotechnology company dedicated to creating and delivering the next
generation of gene editing therapies to patients. The Company is
leveraging its proprietary Prime Editing platform, a versatile,
precise and efficient gene editing technology, to develop a new
class of differentiated, one-time, potentially curative genetic
therapies. Designed to make only the right edit at the right
position within a gene while minimizing unwanted DNA modifications,
Prime Editors have the potential to repair almost all types of
genetic mutations and work in many different tissues, organs and
cell types.
Prime Medicine is currently progressing a diversified portfolio
of eighteen programs initially focused on genetic diseases with a
fast, direct path to treating patients or with a high unmet need
because they cannot be treated using other gene-editing approaches.
Over time, the Company intends to maximize Prime Editing’s
therapeutic potential and advance potentially curative therapeutic
options to patients for a broad spectrum of diseases. For more
information, please visit www.primemedicine.com.
© 2023 Prime Medicine, Inc. All rights reserved. PRIME MEDICINE,
the Prime Medicine logos, and PASSIGE are trademarks of Prime
Medicine, Inc. All other trademarks referred to herein are the
property of their respective owners.
Investor ContactHannah DeresiewiczStern
Investor Relations,
Inc.212-362-1200hannah.deresiewicz@sternir.com
Media ContactDan Budwick,
1ABdan@1ABmedia.com
Prime Medicine (NASDAQ:PRME)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Prime Medicine (NASDAQ:PRME)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024